Susanna High
2022
In 2022, Susanna High earned a total compensation of $1.6M as Chief Operating Officer at Dyne Therapeutics, a 6% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $187,000 |
|---|---|
| Option Awards | $467,116 |
| Salary | $467,500 |
| Stock Awards | $471,680 |
| Other | $996 |
| Total | $1,594,292 |
High received $471.7K in stock awards, accounting for 30% of the total pay in 2022.
High also received $187K in non-equity incentive plan, $467.1K in option awards, $467.5K in salary and $996 in other compensation.
Rankings
In 2022, Susanna High's compensation ranked 2,127th out of 5,756 executives tracked by ExecPay. In other words, High earned more than 63.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,127 out of 5,756 | 63rd |
Division Manufacturing | 1,144 out of 3,133 | 64th |
Major group Chemicals And Allied Products | 491 out of 1,419 | 65th |
Industry group Drugs | 451 out of 1,320 | 66th |
Industry Pharmaceutical Preparations | 326 out of 966 | 66th |
Source: SEC filing on April 7, 2023.
High's colleagues
We found three more compensation records of executives who worked with Susanna High at Dyne Therapeutics in 2022.
News
Dyne Therapeutics CEO Josh Brumm's 2023 pay jumps 38% to $6M
April 5, 2024
Dyne Therapeutics CEO Joshua Brumm's 2022 pay rises 6% to $4.3M
April 7, 2023
Dyne Therapeutics CEO Joshua Brumm's 2021 pay falls 66% to $4.1M
April 22, 2022
Dyne Therapeutics CEO Joshua Brumm's 2020 pay jumps 981% to $12M
April 14, 2021